Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06623409 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).
A Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 5
- Study locations
NCT06623409 is a Phase 1 study of Healthy that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 72 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT06623409, a Phase 1 study of Healthy, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 5
- Study locations
Study Summary
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later. A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540B) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540B in healthy adults and if people tolerate it.
Conditions Studied
Interventions
- BIOLOGICAL GARDASIL®9 (G9)
- BIOLOGICAL V540B
Study Locations (5)
California
- Anaheim Clinical Trials ( Site 0002) - Anaheim
- California Clinical Trials Medical Group managed by PAREXEL ( Site 0008) - Glendale
Florida
- Velocity Clinical Research, Hallandale Beach ( Site 0003) - Hallandale
- Research Centers of America ( Hollywood ) ( Site 0001) - Hollywood
Nebraska
- Velocity Clinical Research, Omaha ( Site 0005) - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2026-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06623409
The ClinicalTrials.gov registry entry for NCT06623409 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which GARDASIL®9 (G9) is the first listed.
NCT06623409 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06623409 about?
NCT06623409 is a clinical study titled "Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).". Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infect...
What is the current status of trial NCT06623409?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-11-12. Estimated completion is 2026-11-20.
What conditions does trial NCT06623409 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT06623409?
The interventions under investigation include: GARDASIL®9 (G9) (BIOLOGICAL), V540B (BIOLOGICAL).
Who is sponsoring clinical trial NCT06623409?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06623409 being conducted?
This trial has 5 study locations across California, Florida, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.